Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based p… Read more
Medipharm Labs Corp (MEDIF) - Total Liabilities
Latest total liabilities as of September 2025: $8.74 Million USD
Based on the latest financial reports, Medipharm Labs Corp (MEDIF) has total liabilities worth $8.74 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medipharm Labs Corp - Total Liabilities Trend (2016–2024)
This chart illustrates how Medipharm Labs Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Medipharm Labs Corp Competitors by Total Liabilities
The table below lists competitors of Medipharm Labs Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tien Liang BioTech Co., Ltd.
TWO:4127
|
Taiwan | NT$745.23 Million |
|
Arogo Capital Acquisition Corp
NASDAQ:AOGO
|
USA | $9.15 Million |
|
First Bancshares Inc. (Bellevue OH)
PINK:FIBH
|
USA | $276.91 Million |
|
Groupe CRIT SA
PA:CEN
|
France | €967.94 Million |
|
Xander International
TWO:6118
|
Taiwan | NT$2.53 Billion |
|
Eclipse Metals Ltd
AU:EPM
|
Australia | AU$120.79K |
|
Ram Technology Co. Ltd
KQ:171010
|
Korea | ₩64.19 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Medipharm Labs Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medipharm Labs Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medipharm Labs Corp (2016–2024)
The table below shows the annual total liabilities of Medipharm Labs Corp from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $10.55 Million | -3.53% |
| 2023-12-31 | $10.93 Million | +15.19% |
| 2022-12-31 | $9.49 Million | +2.98% |
| 2021-12-31 | $9.21 Million | -76.86% |
| 2020-12-31 | $39.82 Million | +5.89% |
| 2019-12-31 | $37.60 Million | +110676.26% |
| 2018-12-31 | $33.95K | -- |
| 2017-12-31 | $0.00 | -- |
| 2016-12-31 | $46.73K | -- |